Sexually Transmitted Infections

Key Points

• STIs affect all populations and may be asymptomatic while still transmissible.
• In U.S. surveillance, adolescents and young adults (about ages 15 to 24) account for a large share of new STI burden.
• Population estimates indicate roughly one in five people in the United States are living with an STI at a given time.
• Prevention includes abstinence, consistent barrier use, vaccination, risk-reduction counseling, and timely testing.
• Major STI groups include bacterial/protozoal infections (for example gonorrhea, chlamydia, trichomoniasis, syphilis) and viral infections (for example HPV, HSV, HIV).
• Nursing priorities include nonjudgmental risk assessment, partner-management education, treatment adherence support, and complication surveillance.

Pathophysiology

STIs are transmitted through sexual contact involving genital, oral, anal, skin, mucosal, or body-fluid exposure. Infection can remain clinically silent while causing tissue inflammation, immune dysregulation, and long-term reproductive sequelae if untreated.

Bacterial and protozoal infections are generally treatable, but delayed care can lead to pelvic inflammatory disease, infertility, ectopic pregnancy risk, chronic pelvic pain, adverse pregnancy outcomes, and enhanced HIV acquisition risk. Viral STIs are often chronic or latent, with management focused on suppression, prevention of transmission, and cancer-risk reduction where applicable.

Screening strategy depends on age, anatomy, sexual practices, and exposure risk. Prevention programs combine behavioral counseling, partner notification/treatment, vaccination, and high-risk interventions such as HIV PrEP.

This framework distinguishes STI (infection state, often asymptomatic) from STD (symptomatic disease expression) and reinforces that asymptomatic carriers can sustain community transmission. Several STIs (including HIV, chlamydia, gonorrhea, syphilis, and chancroid) are nationally notifiable in U.S. public-health reporting systems.

Classification

• Bacterial STIs: Gonorrhea, chlamydia, and syphilis (with stage-dependent manifestations).
• Protozoal STI: Trichomoniasis with reinfection risk and partner-treatment implications.
• Viral STIs: HPV, HSV, HIV, and hepatitis-related transmission contexts.
• Ectoparasitic infestation: Pubic lice with contact transmission and environmental decontamination teaching.
• Complication pathways: PID, infertility, ectopic pregnancy, congenital infection, and systemic disease progression.

Organism-Specific High-Yield Cues

• Chlamydia: Frequently asymptomatic; NAAT urine/swab diagnostics are common; coinfection with gonorrhea is frequent, and perinatal transmission can occur during vaginal birth. Untreated infection can lead to PID and infertility. Reinfection is common, so retesting is recommended about 3 months after treatment.
• Gonorrhea: Can involve genital, rectal, pharyngeal, and conjunctival sites; NAAT/PCR and selected culture pathways are used across anatomic sites (including urine contexts by indication). Counsel abstinence from unprotected sex for at least 7 days after treatment and until partners are treated, retest at about 3 months, and screen for coexisting STIs (for example chlamydia, syphilis, and HIV).
• HIV: Early infection may present with nonspecific flu-like illness (approximately 2-4 weeks after acquisition). ART suppresses viral burden, preserves immune function, and reduces transmission risk. Testing is recommended for all pregnant patients and at least annually for higher-risk groups, with faster linkage to care and partner notification after diagnosis.
• HSV: Vesicular lesions may recur after latency and can transmit during symptomatic outbreaks or asymptomatic shedding. First outbreaks are often the most severe and lesions may persist around one week. NAAT from fresh lesions is preferred; culture may be less sensitive. Suppressive antiviral therapy reduces recurrence burden and transmission probability, and pregnancy contexts require third-trimester suppression planning with cesarean delivery for active genital lesions at labor.
• HPV: Many infections are asymptomatic; selected strains cause genital warts and anogenital/oropharyngeal cancers. More than 100 HPV types are recognized, with variable oncogenic risk profiles. Vaccination is routinely recommended around ages 11-12 with catch-up through age 26, and screening is interval-based (for example, cytology every 3 years for ages 21-29; for ages 30-65, cytology every 3 years, primary HPV testing every 5 years, or co-testing every 5 years in many guideline frameworks).
• Pubic lice: Treat with topical pediculicides (for example permethrin/pyrethrin formulations), avoid sexual contact until treatment completion, and decontaminate clothing/bedding with high-heat wash/dry protocols.
• Syphilis: Progresses through primary/secondary/latent/tertiary stages. Primary disease often presents with a painless chancre that may be overlooked. Secondary manifestations can include flu-like symptoms with highly contagious rash lesions involving palms/soles. Latent disease is asymptomatic (early latent within 12 months; late latent after 12 months). Untreated infection can progress over years (often 10-30 years) to tertiary involvement, including neurologic, ocular, otic, and cardiovascular disease, and can also cause congenital infection in pregnancy. Treatment halts progression but does not reverse established organ damage.
• Syphilis in pregnancy: Can cause intrauterine fetal demise, preterm birth, neonatal death, or congenital syphilis; screen with nontreponemal testing (RPR/VDRL) followed by treponemal confirmation and treat with penicillin-based regimens when indicated.
• Trichomoniasis: Frequently underrecognized and often asymptomatic; routine screening is not universal and is targeted to higher-risk settings or HIV context. Vaginal/urethral swab NAAT is preferred. Typical treatment is oral metronidazole (for example 500 mg twice daily for 7 days in many AFAB contexts, or 2 g single dose in many AMAB contexts), with partner treatment, abstinence until treatment completion and symptom resolution, and retesting at about 3 months in AFAB populations because reinfection is common.
• Pelvic inflammatory disease (PID) linkage: PID can include endometritis, salpingitis, tubo-ovarian abscess, and pelvic peritonitis; early empiric treatment is often favored when clinical suspicion is significant because delayed therapy increases infertility and ectopic-pregnancy risk.

Nursing Assessment

NCLEX Focus

Prioritize exposure risk assessment, anatomic-site specific testing needs, and recognition of asymptomatic transmission risk.

• Use structured sexual-history tools (for example partners, practices, protection, past STIs, pregnancy plans).
• Use a Five P’s interview structure when appropriate: partners, practices, pregnancy intention/prevention, protection, and past STI history.
• Avoid identity-based risk assumptions; determine risk from reported practices and exposure network, including AFAB patients with AFAB partners.
• Screen for high-risk patterns: multiple/new partners, inconsistent condom use, substance-associated risk behavior.
• Include behavior-specific risk cues such as partner concurrency, recent partner STI, transactional sex exposure, and rectal-douching/enema practices before receptive anal sex.
• In adolescents, assess risk-underestimation patterns (for example “it will not happen to me” beliefs) that can drive unprotected-sex decisions.
• Assess symptoms by syndrome cluster (discharge, ulcers, dysuria, pelvic pain, rash, bleeding, fever).
• In suspected syphilis, anticipate dual-serology workflow (nontreponemal test such as RPR/VDRL plus confirmatory treponemal assay), and interpret in context of possible false-positive/false-negative results.
• Evaluate pregnancy status and trimester-specific STI screening requirements.
• In prenatal intake workflows, verify first-visit chlamydia and gonorrhea testing completion and document follow-up plans.
• Screen for trauma, coercion, and intimate partner violence with private, trauma-informed methods.
• In high-exploitation contexts (for example suspected trafficking), prioritize privacy, safety planning, and confidential STI-risk assessment.
• Apply age/risk cadence cues (for example one-time HIV testing for ages 13 to 64, annual chlamydia/gonorrhea testing for sexually active women under 25 or higher-risk women, and comprehensive STI screening in pregnancy).
• For men who have sex with men or persons sharing needles, assess need for at least annual HIV/STI testing with more frequent screening when partner-risk burden is high.

Nursing Interventions

• Provide evidence-based prevention education: condoms, vaccination, testing intervals, and safer-sex planning.
• Reinforce vaccine-prevention pathways relevant to sexual exposure risk (for example hepatitis A/B, HPV, mpox, and meningococcal contexts by indication).
• Reinforce treatment adherence and abstinence guidance during recommended post-treatment windows.
• In genital HSV contexts, teach that condoms reduce but do not eliminate risk, avoid sexual activity during active lesions/prodrome, and discuss suppressive antiviral use for recurrent outbreaks.
• In trichomoniasis contexts, reinforce no sexual activity until the patient and partner(s) have completed therapy and symptoms have resolved; review medication safety teaching such as avoiding alcohol/propylene-glycol exposure during therapy and for 3 days after metronidazole completion.
• Coordinate partner evaluation/treatment pathways according to local policy and legal standards.
• Arrange retesting/test-of-cure where indicated by infection type and pregnancy status.
• Reinforce partner notification/evaluation windows (commonly prior 60 days for chlamydia/gonorrhea contexts) and document public-health reporting requirements per jurisdiction.
• In syphilis contexts, reinforce HIV co-testing, follow-up serologic testing (commonly at about 6 and 12 months), and partner treatment for exposures within approximately 90 days before diagnosis.
• For pregnancy, reinforce required/expected syphilis screening windows (first prenatal visit and third trimester, with higher-risk settings often adding testing at around 28 weeks and at delivery).
• Reinforce that chlamydia and gonorrhea screening are expected at the first prenatal visit, with repeat testing by risk profile.
• In PID treatment contexts, reinforce complete antibiotic course, abstinence until treatment completion and symptom resolution, and reassessment when no clinical improvement occurs within about 72 hours.
• In HIV prevention counseling, assess PrEP eligibility and discuss oral daily versus long-acting injectable options (often administered every 8 weeks) based on adherence fit and access.
• Educate on urgent warning signs of complications (worsening pelvic pain, fever, heavy bleeding, neurologic symptoms).
• During follow-up, evaluate symptom resolution and reinforce expectations for curable versus chronic STI trajectories.
• Provide fertility-impact counseling when history suggests risk of PID-related or recurrent-infection complications.

Asymptomatic-Transmission Trap

Absence of symptoms does not rule out STI infection or contagiousness, so risk-based screening must not be deferred.

Pharmacology

Drug Class	Examples	Key Nursing Considerations
antibiotics	Ceftriaxone, doxycycline, penicillin contexts	Site- and organism-specific regimens require adherence and partner-treatment coordination.
antiviral-medications	Acyclovir and related HSV suppression options	Reduces outbreak burden and transmission risk; reinforce adherence and trigger-based escalation.
antiretroviral-therapy	HIV treatment and PrEP contexts	Sustained adherence reduces morbidity and transmission risk; specialist coordination is essential.

Clinical Judgment Application

Clinical Scenario

A 22-year-old patient presents with mild dysuria and intermittent discharge, reports multiple recent partners, and says they “feel mostly fine” so they delayed testing.

• Recognize Cues: High exposure risk with potentially mild or asymptomatic STI presentation.
• Analyze Cues: Delayed care increases risk of ascending infection and partner transmission.
• Prioritize Hypotheses: Priority is prompt multi-site STI testing and empiric management as indicated by syndrome/risk.
• Generate Solutions: Provide nonjudgmental counseling, testing, treatment plan, and partner notification guidance.
• Take Action: Start guideline-based care and schedule retesting/follow-up.
• Evaluate Outcomes: Symptoms resolve, partner management occurs, and reinfection risk is reduced.

Related Concepts

• vaginal-infections-and-other-conditions - Differential diagnosis of discharge and vulvovaginal symptoms overlaps with STI presentations.
• urinary-tract-infections - Dysuria and pelvic symptoms require STI-versus-UTI differentiation.
• emergency-contraception - STI exposure assessment should accompany unprotected-intercourse visits.
• contraception-the-nurses-role - Dual-protection counseling integrates contraception with STI prevention.
• culturally-competent-care - Stigma-sensitive communication improves disclosure and adherence.

Self-Check

1. Why is symptom-based screening alone insufficient for STI control?
2. Which STI management plans require partner presumptive treatment and retesting?
3. How does nursing counseling reduce reinfection and long-term reproductive complications?